← Back to Search

Antidote

Low for High Blood Pressure

Phase 4
Waitlist Available
Led By Deepak Malhotra, MD, PhD
Research Sponsored by National Institute on Aging (NIA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screening, and after first and second infusions
Awards & highlights

Study Summary

The purpose of this study is to examine the effects of the digibind drug on hemodialysis patients with high blood pressure. Digibind is used to treat toxicity from digoxin and digoxin-like molecules which may contribute to high blood pressure.

Eligible Conditions
  • High Blood Pressure
  • Hemodialysis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening, and 24-hour period after first infusion and after second infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and screening, and 24-hour period after first infusion and after second infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Blood pressure
Secondary outcome measures
Marinobufagenin levels

Side effects data

From 2018 Phase 4 trial • 178 Patients • NCT03136068
2%
hemmorhage
1%
pregnancy labor
1%
fever
1%
cramping
1%
severe nausea
1%
vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Digoxin
Placebo

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: MediumExperimental Treatment1 Intervention
0.4mg/kg
Group II: LowExperimental Treatment1 Intervention
0.1mg/kg
Group III: HighExperimental Treatment1 Intervention
1.6 mg/kg
Group IV: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)Lead Sponsor
1,679 Previous Clinical Trials
28,021,632 Total Patients Enrolled
University of Toledo Health Science CampusOTHER
40 Previous Clinical Trials
16,590 Total Patients Enrolled
Deepak Malhotra, MD, PhDPrincipal InvestigatorUniversity of Toledo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease
2009. "Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00852787.
All > Digoxin
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top